MXPA05006989A - Derivados de diamina. - Google Patents

Derivados de diamina.

Info

Publication number
MXPA05006989A
MXPA05006989A MXPA05006989A MXPA05006989A MXPA05006989A MX PA05006989 A MXPA05006989 A MX PA05006989A MX PA05006989 A MXPA05006989 A MX PA05006989A MX PA05006989 A MXPA05006989 A MX PA05006989A MX PA05006989 A MXPA05006989 A MX PA05006989A
Authority
MX
Mexico
Prior art keywords
thrombosis
represent
syndrome
infarction
blood
Prior art date
Application number
MXPA05006989A
Other languages
English (en)
Inventor
Makoto Ono
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32684223&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05006989(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of MXPA05006989A publication Critical patent/MXPA05006989A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto representado por la siguiente formula general (l): (ver formula (l)), Q1-Q2-T0N(R1)-Q3N(R2)-T1Q4(1) en donde R1 y R2 representa cada uno hidrogeno, etc.; Q1 representa opcionalmente hidrocarbilo ciclico de 5 a 6 elementos saturado o insaturado, etc.; Q2 representa un solo enlace, etc.; Q3 representa un grupo de la siguiente formula: (en donde Q5 representa alquileno de C1-8 etc.; y T0 y T1 representan cada uno carbonilo, etc.; su sal, solvatos de los mismos o N- oxidos de los mismos; estos compuestos son utiles como preventivos y/o remedios para infarto cerebral, embolia cerebral, infarto al miocardio, angina, infarto pulmonar, embolia pulmonar, enfermedad de Burger, trombosis venosa profunda, sindrome de coagulacion intravascular diseminada, trombosis despues del reemplazo de valvula/articulacion artificial, trombosis y reoclusion despues de reconstruir la circulacion sanguinea, sindrome de respuesta inflamatoria sistemica (SIRS), sindrome de disfuncion multiorganica (MODS), trombosis en circulacion extracorporea y coagulacion sanguinea en recoleccion sanguinea.
MXPA05006989A 2002-12-25 2003-12-25 Derivados de diamina. MXPA05006989A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002373787 2002-12-25
JP2003379163 2003-11-07
PCT/JP2003/016783 WO2004058715A1 (ja) 2002-12-25 2003-12-25 ジアミン誘導体

Publications (1)

Publication Number Publication Date
MXPA05006989A true MXPA05006989A (es) 2005-09-22

Family

ID=32684223

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006989A MXPA05006989A (es) 2002-12-25 2003-12-25 Derivados de diamina.

Country Status (14)

Country Link
US (3) US7576135B2 (es)
EP (1) EP1577301B1 (es)
JP (2) JP4109288B2 (es)
KR (1) KR20050110612A (es)
AU (1) AU2003292828B9 (es)
CA (1) CA2511493A1 (es)
ES (1) ES2393996T3 (es)
HK (1) HK1086006A1 (es)
IL (1) IL169349A0 (es)
MX (1) MXPA05006989A (es)
PL (1) PL377550A1 (es)
RU (1) RU2333203C2 (es)
TW (1) TW200500366A (es)
WO (1) WO2004058715A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
WO2004058715A1 (ja) * 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. ジアミン誘導体
JP4630267B2 (ja) * 2002-12-25 2011-02-09 第一三共株式会社 ジアミン誘導体
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
JP4759388B2 (ja) 2003-11-12 2011-08-31 第一三共株式会社 チアゾール誘導体の製造法
US9212149B2 (en) 2004-04-30 2015-12-15 Takeda Pharmaceutical Company Limited Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
EA200700251A1 (ru) * 2004-08-10 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве фармацевтических средств
IT1362675B (it) * 2005-03-15 2009-06-25 Menarini Internat Operations Luxembourg Sa N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
JP4926949B2 (ja) * 2005-03-31 2012-05-09 第一三共株式会社 トリアミン誘導体
DE102005032209A1 (de) * 2005-07-09 2007-01-18 Lanxess Deutschland Gmbh 1-Cycloalkyl-5-Iodtetrazole
US20070032473A1 (en) * 2005-07-19 2007-02-08 Kai Gerlach Substituted amides and their use as medicaments
CN103214414B (zh) * 2005-09-16 2016-02-17 第一三共株式会社 旋光性的二胺衍生物及其制造方法
CA2627426A1 (en) * 2005-11-11 2007-05-18 Markus Boehringer Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
AU2006314637A1 (en) 2005-11-16 2007-05-24 F. Hoffmann-La Roche Ag Novel pyrrolidine derivatives as inhibitors of coagulation factor Xa
DE102005062990A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
JP5187901B2 (ja) 2006-08-30 2013-04-24 塩野義製薬株式会社 ヒドラジンアミド誘導体
PL2140867T5 (pl) 2007-03-29 2023-10-30 Daiichi Sankyo Company, Limited Kompozycja farmaceutyczna
WO2010058751A1 (ja) * 2008-11-18 2010-05-27 第一三共株式会社 [１,３,４]オキサジアゾール化合物の薬理上許容される塩又はその水和物
BRPI0922434A2 (pt) 2008-12-12 2015-12-15 Daiichi Sankyo Co Ltd processo para produzir ácido carboxílico opticamente ativo
BRPI0923109A8 (pt) 2008-12-17 2016-06-07 Daiichi Sankyo Co Ltd método para a produção de derivados de diamina
JPWO2010071164A1 (ja) 2008-12-19 2012-05-31 第一三共株式会社 活性化血液凝固第Ｘ因子（ＦＸａ）阻害剤
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
ES2542236T3 (es) 2009-03-10 2015-08-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de diamina
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
JPWO2010147169A1 (ja) 2009-06-18 2012-12-06 第一三共株式会社 溶出性の改善された医薬組成物
TWI500623B (zh) 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
US8541430B2 (en) * 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones
EP2540317A4 (en) 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION
TW201200165A (en) 2010-02-22 2012-01-01 Daiichi Sankyo Co Ltd Oral solid extended release dosage form
TW201141544A (en) * 2010-02-22 2011-12-01 Daiichi Sankyo Co Ltd Oral solid extended release dosage form
EP2548556B1 (en) 2010-03-19 2016-08-10 Daiichi Sankyo Company, Limited Method for improving dissolvability of anticoagulant
BR112012023649B1 (pt) 2010-03-19 2021-06-08 Daiichi Sankyo Company, Limited Método para produção de cristais de forma ii de monoidrato de n1 -(5-cloropiridin-2-il)-n2 -((1s,2r,4s)-4-[(dimetilamino) carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino}ciclohexil)etanodiamida p-toluenossulfonato
CN102858764B (zh) * 2010-04-27 2014-08-20 和记黄埔医药（上海）有限公司 嘧啶基吲哚化合物
HUE031961T2 (en) 2010-07-02 2017-09-28 Daiichi Sankyo Co Ltd A method for preparing an optically active salt of diamine derivative
HUE035506T2 (en) 2010-08-04 2018-05-02 Daiichi Sankyo Co Ltd Process for Preparing a Compound with a New Sandmeyer-Type Reaction Using a Nitric Dioxide Compound as a Reaction Catalyst
CA2844604C (en) 2011-08-10 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ethanediamide derivatives
WO2014034929A1 (ja) 2012-09-03 2014-03-06 第一三共株式会社 ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物
TWI602803B (zh) 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
CN104936961B (zh) 2013-03-29 2016-10-26 第一三共株式会社 (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法
KR102371784B1 (ko) 2014-02-18 2022-03-07 다이이찌 산쿄 가부시키가이샤 활성화 혈액 응고 제 X 인자 (FXa) 의 저해약의 제조 방법
KR20180022125A (ko) * 2016-08-23 2018-03-06 동화약품주식회사 디아민 유도체의 산부가염 및 이의 제조 방법
KR102333564B1 (ko) 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
WO2022129535A1 (en) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Edoxaban formulation containing no sugar alcohols

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3376268A (en) * 1964-02-26 1968-04-02 Monsanto Co Amide-heterocyclic polymers
JP2875930B2 (ja) * 1992-12-02 1999-03-31 富士写真フイルム株式会社 旋光フイルムおよびそれを用いた液晶表示装置
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
DE69426602T2 (de) * 1993-10-19 2001-08-30 Sumitomo Pharma 2,3-diaminopropionsäurederivate
US5525042A (en) * 1993-11-08 1996-06-11 Clearline Systems, Inc. Liquid pump with compressed gas motive fluid
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
DE19536783A1 (de) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
US5852045A (en) * 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
US5668159A (en) * 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
AU7453498A (en) * 1997-05-30 1998-12-30 Takeda Chemical Industries Ltd. Sulfonamide derivatives, their production and use
JP4256065B2 (ja) 1997-09-30 2009-04-22 第一三共株式会社 スルホニル誘導体
US6130349A (en) * 1997-12-19 2000-10-10 The Board Of Trustees Of The Leland Stanford Junior University Catalytic compositions and methods for asymmetric allylic alkylation
DE19814801A1 (de) * 1998-04-02 1999-10-07 Basf Ag Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen
TW434207B (en) * 1998-07-24 2001-05-16 Everlight Chem Ind Corp Chiral ligand and method for preparing cyanohydrins from aldehydes
EP1104754A1 (en) 1998-08-11 2001-06-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
GB9909592D0 (en) * 1999-04-26 1999-06-23 Chirotech Technology Ltd Process for the preparation of calanolide precursors
US6797720B2 (en) * 1999-12-03 2004-09-28 Ono Pharmaceutical Co., Ltd. 1,3,4-oxadiazoline derivative and an agent comprising its derivative as active ingredient
CA2400183A1 (en) * 2000-02-10 2001-08-16 The Penn State Research Foundation Chiral ferrocene phosphines and their use in asymmetric catalytic reactions
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
JP4128138B2 (ja) * 2001-06-20 2008-07-30 第一三共株式会社 ジアミン誘導体
BR0211565A (pt) * 2001-08-09 2004-06-29 Daiichi Seiyaku Co Derivados de diamina
UA78232C2 (uk) * 2001-09-21 2007-03-15 Брістол-Майерс Сквібб Компані Лактамвмісні сполуки та їх похідні як інгібітори фактора ха
JP4266092B2 (ja) 2001-10-09 2009-05-20 第一三共株式会社 ジアミン誘導体
AU2002350217A1 (en) * 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
GB0205170D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7312214B2 (en) * 2002-05-10 2007-12-25 Bristol-Myers Squibb Company 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
SI1511710T1 (sl) * 2002-05-31 2014-04-30 Proteotech, Inc. Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
CN1745071A (zh) * 2002-12-24 2006-03-08 第一制药株式会社 新型乙二胺衍生物
WO2004058715A1 (ja) 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. ジアミン誘導体

Also Published As

Publication number Publication date
ES2393996T3 (es) 2013-01-04
US20090281074A1 (en) 2009-11-12
PL377550A1 (pl) 2006-02-06
AU2003292828A1 (en) 2004-07-22
EP1577301B1 (en) 2012-09-12
CA2511493A1 (en) 2004-07-15
EP1577301A4 (en) 2009-11-11
JP2008138011A (ja) 2008-06-19
US20060252837A1 (en) 2006-11-09
AU2003292828B2 (en) 2009-09-10
JP4809850B2 (ja) 2011-11-09
RU2333203C2 (ru) 2008-09-10
US7576135B2 (en) 2009-08-18
RU2005123394A (ru) 2006-05-27
IL169349A0 (en) 2007-07-04
JP4109288B2 (ja) 2008-07-02
EP1577301A1 (en) 2005-09-21
HK1086006A1 (en) 2006-09-08
KR20050110612A (ko) 2005-11-23
US20100099660A1 (en) 2010-04-22
AU2003292828B9 (en) 2009-10-01
TW200500366A (en) 2005-01-01
WO2004058715A1 (ja) 2004-07-15
JPWO2004058715A1 (ja) 2006-04-27

Similar Documents

Publication Publication Date Title
MXPA05006989A (es) Derivados de diamina.
MXPA04001272A (es) Derivados de diamina.
MXPA03011951A (es) Derivados de diamina.
MY153231A (en) Diamine derivatives
EA200200194A1 (ru) Антагонисты хемокинного рецептора и способы их применения
EP0370498A3 (en) Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof
ATE291013T1 (de) Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten
LU90562I2 (fr) Acides imidazoalc-noiques
TW200510369A (en) Novel ethylenediamine derivatives
YU205590A (sh) Amidi imidazo (4,5-b)hinolinoloksi alkanovih kiselina sa poboljšanom rastvorljivošću u vodi i postupak za dobijanje
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
MA28012A1 (fr) Derives de pyridyle et utilisation de ceux-ci en tant qu'agents therapeutiques
RS50876B (sr) Upotreba flibanserina u lečenju seksualnih poremećaja
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
LV12634A (lv) Watersoluble azole antifungals
EA200200952A1 (ru) Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов
SE9703414D0 (sv) New compounds
EA200200348A1 (ru) Фармацевтические растворы левосимендана
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
DE60227283D1 (de) Substituierte diketopiperazine als oxytocin-antagonisten
DK1377164T3 (da) Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo
EA200201158A1 (ru) Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
EA200000693A1 (ru) Антагонисты хемокинного рецептора и способы их применения

Legal Events

Date Code Title Description
FG Grant or registration